Time Sensitive Archives - EverGlade Consulting

Time Sensitive

antimicrobial-resistant (AMR) pathogens and viruses

NIAID Omnibus Broad Agency Announcement (BAA)

Leave a Comment / EverGlade Insights, NIAID, Time Sensitive / By

Pre-solicitation_Notice_-_BAA2025-1_Final Overview of Solicitation The upcoming 2026 Omnibus Broad Agency Announcement (BAA) is from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH) under the Department of Health and Human Services (DHHS). NIAID’s mission centers on understanding, treating, and preventing infectious, immunologic, and allergic diseases. Through […]

NIAID Omnibus Broad Agency Announcement (BAA) Read More »

Marburg virus (MARV) and Sudan virus (SUDV) vaccines clinical trials

BARDA Issues Sources Sought Notice for Marburg Virus and Sudan Virus Vaccines

Leave a Comment / BARDA, EverGlade Insights, Time Sensitive / By

SSN_MARV__SUDV_Vaccines Purpose The Biomedical Advanced Research and Development Authority (BARDA), under the Administration for Strategic Preparedness and Response (ASPR) has issued a Sources Sought Notice (SSN). The subject of this SSN is Marburg virus (MARV) and Sudan virus (SUDV) vaccines in active or completed Phase 2 clinical trials. Insights on current and prospective MARV and

BARDA Issues Sources Sought Notice for Marburg Virus and Sudan Virus Vaccines Read More »

curative cell therapies_DECIDE-ET_ARPA-H

Decentralized Engineering of Cells Informed by Dynamic Evidence Exploration Topic

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By

ARPA-H_DECIDE-ET_Solicitation_DRAFT Overview of Exploration Topic Although Academic Medical Centers (AMCs) have developed many advanced therapies for rare and fatal diseases,  access to AMCs remains limited due to outdated production methods and inadequate quality validation. To enhancing quality assurance technologies at AMCs, the Advanced Research Projects Agency for Health (ARPA-H) has initiated the Decentralized Engineering of

Decentralized Engineering of Cells Informed by Dynamic Evidence Exploration Topic Read More »

in silico modeling for ADME-Tox simulation

Computational ADME-Tox Analysis for Safer Therapeutics (CATALYST) Innovative Solutions Opening

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By

CATALYST_ISO_(DRAFT) Overview of CATALYST Solicitation Current in vivo animal model testing methods often fail to predict human drug safety accurately, leading to inefficiencies and high costs. The Health Science Futures (HSF) Office of the Advanced Research projects Agency for Health (ARPA-H) has introduced the CATALYST program to transform drug development. This program will foster the

Computational ADME-Tox Analysis for Safer Therapeutics (CATALYST) Innovative Solutions Opening Read More »

Artificial Intelligence (AI) and Machine Learning (ML) innovations

DARPA Releases Strategic Catalyst Announcement for AI BTO

Leave a Comment / DARPA, EverGlade Insights, Time Sensitive / By

DARPA-SCA-24-01 The Biological Technologies Office (BTO) of the Defense Advanced Research Projects Agency (DARPA) recently released a Strategic Catalyst Announcement (SCA) titled AI BTO (Funding Opportunity Number: DARPA-SCA-24-01). AI BTO encourages participation by new or non-traditional proposers to leverage Artificial Intelligence (AI) and Machine Learning (ML) innovations for the BTO. Overview of AI BTO AI

DARPA Releases Strategic Catalyst Announcement for AI BTO Read More »

cell therapies

ARPA-H Issues Draft Solicitation for Autologous Cell Therapy (ACT)

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By

DECIDE_ET_Solicitation_DRAFT The Advanced Research Projects Agency for Health (ARPA-H) has introduced the Decentralized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic (ET), representing a crucial initiative designed to revolutionize the production and validation of autologous cell therapies. This ET targets significant enhancements in the production processes at Academic Medical Centers (AMCs), focusing on

ARPA-H Issues Draft Solicitation for Autologous Cell Therapy (ACT) Read More »

cancer screening technologies

ARPA-H Announces RFP for Cancer Intervention and Detection

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By

24-SOL-109+POSEIDON+DRAFT+ISO_9+AUG+24 The Advanced Research Projects Agency for Health (ARPA-H) has issued a Request for Proposals (RFP) for the POSEIDON program, a groundbreaking initiative aimed at advancing cancer screening technologies. The Platform Optimizing SynBio for Early Intervention and Detection in Oncology (POSEIDON) seeks to develop innovative, non-invasive tests that can detect multiple cancers at an early

ARPA-H Announces RFP for Cancer Intervention and Detection Read More »

Filovirus Monoclonal Antibodies

BARDA Announces RPP for Manufacturing Optimization for Filovirus Monoclonal Antibodies

Leave a Comment / BARDA, EverGlade Insights, Time Sensitive / By

The Biomedical Advanced Research and Development Authority (BARDA) has issued a Request for Project Proposals (RPP) for “Manufacturing Optimization for Filovirus Monoclonal Antibodies.” The RPP was released on June 24, 2024, with proposals due by July 22, 2024. This initiative aims to enhance the manufacturing development of monoclonal antibody (mAb) cocktails targeting filoviruses like Ebola and Marburg viruses.

BARDA Announces RPP for Manufacturing Optimization for Filovirus Monoclonal Antibodies Read More »

DARPA’s B-SAFE Industry Day

Join DARPA’s B-SAFE Industry Day for Groundbreaking Advances in Gene Editing Inhibitors

Leave a Comment / DARPA, EverGlade Insights, Time Sensitive / By

The Defense Advanced Research Projects Agency is hosting an Industry Day for the B-SAFE (Broad-Spectrum Antagonists for Editors) program on June 28, 2024, in Arlington, VA, with a webinar option available. This event is pivotal for those in the science and technology communities, including industry, academia, and government, who are interested in advancing gene editing technologies.

Join DARPA’s B-SAFE Industry Day for Groundbreaking Advances in Gene Editing Inhibitors Read More »

Wearable medical device

ARPA-H Solicits Proposals For REACT Program

Leave a Comment / ARPA-H, EverGlade Insights, Time Sensitive / By

Advanced Research Projects Agency (ARPA-H) Solicits Proposals for Resilient Extended Automatic Cell Therapies (REACT) Program The Advanced Research Projects Agency for Health (ARPA-H) is actively seeking innovative proposals through the Resilient Extended Automatic Cell Therapies (REACT) program, employing a Master Announcement Instruction (MAI) strategy for proposal submissions. This strategy enables proposers to tailor their submissions

ARPA-H Solicits Proposals For REACT Program Read More »

Female scientist in a hazmat suit researching WMD-related security challenges

DTRA BAA Weapons of Mass Destruction Amendment

Leave a Comment / DTRA, EverGlade Insights, Time Sensitive / By

DTRA BAA Outlines New Opportunity to Identify and Counter Weapons of Mass Destruction (WMD) through the Strategic Trends Research Initiative The Defense Threat Reduction Agency (DTRA) has amended its Broad Agency Announcement (BAA) to offer new funding opportunities through the Strategic Trends Research Initiative (STRI) for identifying and countering Weapons of Mass Destruction (WMD), defined

DTRA BAA Weapons of Mass Destruction Amendment Read More »

CHIPS Act Funding Alert

CHIPS Act Pre-Funding Alert

Leave a Comment / CHIPS, Time Sensitive / By

CHIPS Act Program Begins Accepting Pre-Applications for Large Supply Chain Projects In a move to secure America’s leadership in the semiconductor sector, the U.S. Department of Commerce (DoC) announced on Friday, the start of its rolling pre-application process for large-scale supply chain projects and wafer manufacturing facilities. The projects that qualify must have capital investments

CHIPS Act Pre-Funding Alert Read More »

Scroll to Top